The authors comment with interest on the article by David Kavanagh and colleagues showing that the complement factor B inhibitor iptacopan significantly reduces proteinuria in patients with C3 glomerulopathy. With its approval, the scope of complement inhibitors expands to diseases that were previously not considered complement-mediated or untreatable. They highlight the emerging role of these drugs in such conditions. The authors commend the comprehensive monitoring of complement and biomarkers during repeated iptacopan therapy. The correspondence points to the importance of monitoring these parameters in clinical practice.